“Drug companies, meet reality,” said Erik Gordon, an analyst and professor at University of Michigan’s Ross School of Business. “There isn’t enough money to pay $100,000 for therapies that don’t show massive benefits, unless there is a politically powerful patient advocacy group behind it.”
Analyst Krishnan said she wasn’t sure if patient and doctor protests would ultimately convince NICE to recommend Yervoy, but acknowledged it was a possibility. “They are in a very difficult position,” she said. “They are increasingly just looking at the cost, but the pressure from the public can be very powerful.”
_____
AP Business Writer Linda A. Johnson in Trenton, New Jersey, contributed to this report.
Independent voices from the TWT Communities
A collection of reader guest articles, thoughts and opinions by Communities writers and breaking news and information.
In a world that is increasingly complex, we need to seek greater awareness of the blending of cultures and America's changing role in a global community.
World's Ugliest Dog Contest
26 Photos
Spelling Bee finale
45 Photos
Marines train Afghan soldiers
4 Photos
Rolling Thunder 2013
24 Photos
Benghazi: The anatomy of a scandal
13 Photos
